ArticleBMC neurology2026
Glymphatic dysfunction and its association with clinical symptom severity in narcolepsy type 1: a case-control DTI-ALPS study.
Article in BMC neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Association between obstructive sleep apnea severity and glymphatic-related DTI-ALPS alterations in newly diagnosed, Drug-Naïve Alzheimer's disease.The journal of prevention of Alzheimer's disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNarcolepsy type 1 (NT1) is characterized by excessive daytime sleepiness and cataplexy, primarily caused by hypothalamic orexin deficiency. Beyond neurotransmitter dysregulation, recent evidence suggests that impaired metabolic waste clearance may contribute to its pathophysiology. This study aimed to assess glymphatic function in NT1 using diffusion tensor image analysis along the perivascular space (DTI-ALPS) and to explore its relationship with clinical and polysomnographic features.
methodsA total of 92 NT1 patients and 45 age- and sex-matched healthy controls underwent 3.0 T DTI and overnight polysomnography. The ALPS index was calculated to quantify glymphatic efficiency. Correlation and regression analyses examined associations between ALPS values and Epworth Sleepiness Scale (ESS), Multiple Sleep Latency Test (MSLT), and other clinical parameters. Receiver operating characteristic (ROC) analysis evaluated the predictive performance of ALPS for NT1 diagnosis.
resultsThe ALPS index was significantly lower in NT1 patients than in controls (1.24 ± 0.07 vs. 1.33 ± 0.06, P < 0.001), indicating impaired glymphatic function. Reduced ALPS values correlated with higher ESS scores (r = − 0.39, P < 0.001), shorter MSLT latency (r = 0.36, P = 0.002), and greater cataplexy severity. Each 0.1-unit decrease in ALPS increased the odds of NT1 by 2.8-fold (adjusted OR = 2.78, 95% CI 1.43–5.41, P = 0.003). The ALPS index showed good diagnostic accuracy (AUC = 0.81), which improved when combined with MSLT (AUC = 0.87, P = 0.018).
conclusionsNT1 is associated with significant glymphatic dysfunction, and the degree of impairment correlates with symptom severity. The DTI-ALPS index provides a quantitative and noninvasive biomarker that may aid in disease evaluation and individualized management of narcolepsy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.